| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | F8A1 |
| Uniprot No | P23610 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-371aa |
| 氨基酸序列 | AAAAAGLGG GGAGPGPEAG DFLARYRLVS NKLKKRFLRK PNVAEAGEQF GQLGRELRAQ ECLPYAAWCQ LAVARCQQAL FHGPGEALAL TEAARLFLRQ ERDARQRLVC PAAYGEPLQA AASALGAAVR LHLELGQPAA AAALCLELAA ALRDLGQPAA AAGHFQRAAQ LQLPQLPLAA LQALGEAASC QLLARDYTGA LAVFTRMQRL AREHGSHPVQ SLPPPPPPAP QPGPGATPAL PAALLPPNSG SAAPSPAALG AFSDVLVRCE VSRVLLLLLL QPPPAKLLPE HAQTLEKYSW EAFDSHGQES SGQLPEELFL LLQSLVMATH EKDTEAIKSL QVEMWPLLTA EQNHLLHLVL QETISPSGQG V |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于F8A1重组蛋白的模拟参考文献(注：文献信息为示例性生成，实际文献需查询数据库验证)：
---
1. **文献名称**: *"Recombinant F8A1 Protein Expression and Functional Characterization in Hemophilia A Models"*
**作者**: Zhang L, et al.
**摘要**: 本研究利用哺乳动物细胞系统成功表达并纯化F8A1重组蛋白，验证其在凝血因子VIII缺失模型中的促凝血活性。结果显示重组F8A1可部分恢复血友病A小鼠的凝血功能，为基因治疗提供潜在靶点。
---
2. **文献名称**: *"Structural Analysis of F8A1 Domain in Factor VIII Using Recombinant Protein Technology"*
**作者**: Patel R, Smith J.
**摘要**: 通过X射线晶体学解析重组F8A1蛋白的三维结构，揭示其与凝血因子VIII其他结构域的相互作用界面，为理解F8A1在凝血级联反应中的分子机制提供结构基础。
---
3. **文献名称**: *"Optimization of F8A1 Recombinant Protein Production in E. coli for Therapeutic Applications"*
**作者**: Kim H, et al.
**摘要**: 报道在大肠杆菌中高效表达可溶性F8A1重组蛋白的优化策略，通过密码子优化和温度调控提高产量，并验证其体外抗凝血抗体结合能力，为规模化生产奠定基础。
---
如需真实文献，建议在PubMed或Google Scholar中搜索关键词：**"F8A1 recombinant protein"** 或 **"Factor VIII A1 domain recombinant"**。
**Background of F8A1 Recombinant Protein**
F8A1 (Factor VIII-associated 1) is a gene located within intron 22 of the *F8* gene on the X chromosome, which encodes coagulation factor VIII (FVIII) — a critical blood-clotting protein. The *F8A1* gene is part of a unique genomic arrangement involving two additional homologous sequences (*F8A2* and *F8A3*) in the same region. These sequences contribute to a common inversion mutation (intron 22 inversion) responsible for ~45% of severe hemophilia A cases, an X-linked bleeding disorder caused by FVIII deficiency.
The F8A1 protein, though not directly involved in coagulation, has been studied for its role in this inversion event. Recombinant F8A1 protein is produced via genetic engineering to investigate its structural and functional properties. Its production typically involves inserting the *F8A1* gene into expression vectors (e.g., bacterial, yeast, or mammalian systems) to enable large-scale synthesis. Purification methods like affinity chromatography ensure high purity for research applications.
Studies on F8A1 recombinant protein focus on understanding its interaction with other genomic elements during homologous recombination, which underlies the pathogenic inversion. Additionally, it serves as a tool for developing diagnostic assays to detect intron 22 inversions in hemophilia A patients. While F8A1 itself is not therapeutic, insights from its recombinant form aid in advancing gene therapy strategies for hemophilia A, such as CRISPR-based correction of inversion defects or improving FVIII expression vectors.
Overall, F8A1 recombinant protein bridges basic research and clinical applications, offering a model to dissect genetic mechanisms and innovate therapies for coagulation disorders.
×
